Dec 17, 2018
Jesús Martin-Garcia, CEO, GeNeuro discusses the need for new treatment approaches for multiple sclerosis (MS), a long lasting, often disabling disease of the central nervous system that affects 2.5 million people worldwide. GeNeuro is developing a potential new approach for treating disease progression, the largest...
Dec 10, 2018
Dr. Patrik De Haes, CEO, Oxurion discusses the need for new treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. About half of patients living with diabetic eye disease respond poorly or do not respond at all to the current standard of care. Oxurion is working to...
Dec 4, 2018
Elad Kedar, CEO, Orasis discusses CSF-1, the company's corrective eye drop being developed for the treatment of presbyopia as an alternative to reading glasses. Presbyopia, the inability to focus on near objects, is common after the age of 40 and affects more than 1.8 billion people worldwide. While glasses have been...